Back to top

Surging Earnings Estimates Signal Upside for SurModics (SRDX) Stock

Read MoreHide Full Article

SurModics (SRDX - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.

The upward trend in estimate revisions for this drug delivery technology company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For SurModics, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

For the current quarter, the company is expected to earn $0.08 per share, which is a change of +60% from the year-ago reported number.

Over the last 30 days, one estimate has moved higher for SurModics compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 33.33%.

Current-Year Estimate Revisions

The company is expected to earn $0.42 per share for the full year, which represents a change of -14.29% from the prior-year number.

There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, one estimate has moved up for SurModics versus no negative revisions. This has pushed the consensus estimate 40% higher.

Favorable Zacks Rank

The promising estimate revisions have helped SurModics earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

SurModics shares have added 5.3% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Surmodics, Inc. (SRDX) - free report >>

Published in